Article
Medicine, General & Internal
Oliver Sartor, Johann de Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El-Haddad, Chandler H. Park, Tomasz M. Beer, Alison Armour, Wendy J. Perez-Contreras, Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Michael J. Morris, Bernd J. Krause
Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Radiology, Nuclear Medicine & Medical Imaging
Swayamjeet Satapathy, Ranjit K. Sahoo, Chandrasekhar Bal
Summary: This study aimed to evaluate the impact of prior taxane chemotherapy on response and survival outcomes in mCRPC patients after [177Lu]Lu-PSMA-RLT. Results showed that taxane-naive patients had significantly better outcomes in terms of biochemical response rate, progression-free survival, and overall survival after [177Lu]Lu-PSMA-RLT. Further trials in the taxane-naive setting are required to confirm these findings.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Viviane J. Tschan, Francesca Borgna, Sarah D. Busslinger, Martina Stirn, Josep M. Monne Rodriguez, Peter Bernhardt, Roger Schibli, Cristina Muller
Summary: This study investigated [Lu-177]Lu-Ibu-DAB-PSMA in preclinical in vivo experiments and compared its therapeutic efficacy and potential side effects with other radioligands. The results showed that [Lu-177]Lu-Ibu-DAB-PSMA was more effective in inhibiting tumor growth compared to [Lu-177]Lu-PSMA-617, and had a better safety profile than [Lu-177]Lu-PSMA-ALB-56. These findings suggest that [Lu-177]Lu-Ibu-DAB-PSMA has potential for clinical translation.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Christiane Schuchardt, Jingjing Zhang, Harshad R. Kulkarni, Xiaoyuan Chen, Dirk Mueller, Richard P. Baum
Summary: The objective of this study was to assess the safety, kinetics, and dosimetry of Lu-177-labeled PSMA small molecules (Lu-177-PSMA I&T and Lu-177-PSMA-617) in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing PSMA radioligand therapy (PRLT). The study showed that both Lu-177-PSMA I&T and Lu-177-PSMA-617 demonstrated favorable safety and comparable absorbed tumor doses. However, there was variability in dosimetry parameters between patients, suggesting the need for personalized dosimetry in PRLT.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Wojciech Cytawa, Robin Hendel, Bartlomiej Tomasik, Franz-Xaver Weinzierl, Thorsten Bley, Jacek Jassem, Andreas Schirbel, Andreas K. Buck, Ralph A. Bundschuh, Philipp E. Hartrampf, Rudolf A. Werner, Constantin Lapa
Summary: The purpose of this study was to investigate the radiographic PSMA PET response after one cycle of [Lu-177]Lu-PSMA I & T RLT in mCRPC patients and to assess its role in predicting overall response and survival. The results showed that early PSMA PET radiographic response was not associated with overall survival, indicating that treatment should not be discontinued prematurely. However, early PSA progression after one cycle of [Lu-177]Lu-PSMA I & T RLT was an indicator of overall progression and poor clinical outcome.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Song Xue, Andrei Gafita, Chao Dong, Yu Zhao, Giles Tetteh, Bjoern H. Menze, Sibylle Ziegler, Wolfgang Weber, Ali Afshar-Oromieh, Axel Rominger, Matthias Eiber, Kuangyu Shi
Summary: This study aimed to prove the concept of pretherapeutic prediction of dosimetry based on imaging and laboratory measurements before prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT). Machine learning methods were explored for dose prediction using organ SUVs and laboratory measurements. The preliminary results confirmed the feasibility of pretherapeutic estimation of treatment dosimetry and its added value to empirical population-based estimation.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Thorsten Derlin, Liam Widjaja, Rudolf A. Werner, Frank M. Bengel
Summary: The study aimed to evaluate the feasibility, additional benefit, and toxicity of extending prostate-specific membrane antigen (PSMA) targeted radioligand therapy in patients with metastatic castration-resistant prostate cancer. The results showed that extending the treatment could achieve additional therapeutic effect with mild toxicity. Therefore, treatment extension is feasible and effective for patients with metastatic castration-resistant prostate cancer.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Oncology
Bastiaan M. Prive, Steffie M. B. Peters, Constantijn H. J. Muselaers, Inge M. van Oort, Marcel J. R. Janssen, J. P. Michiel Sedelaar, Mark W. Konijnenberg, Patrik Zamecnik, Maike J. M. Uijen, Melline G. M. Schilham, Annemarie Eek, Tom W. J. Scheenen, J. Fred Verzijlbergen, Winald R. Gerritsen, Niven Mehra, Linda G. W. Kerkmeijer, Robert J. Smeenk, Diederik M. Somford, Jean-Paul A. Van Basten, Sandra Heskamp, Jelle O. Barentsz, Martin Gotthardt, J. Alfred Witjes, James Nagarajah
Summary: In this prospective study, Lu-177-PSMA appeared to be a feasible and safe treatment modality for patients with low-volume metastatic hormone-sensitive prostate cancer, showing good treatment effect and minimal adverse events.
CLINICAL CANCER RESEARCH
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Luka Flegar, Smita George Thoduka, Damiano Librizzi, Markus Luster, Aristeidis Zacharis, Hendrik Heers, Nicole Eisenmenger, Hojjat Ahmadzadehfar, Matthias Eiber, Wolfgang Weber, Christer Groeben, Johannes Huber
Summary: This study examines the adoption and current trends of Lutetium-(177) PSMA RLT for mCRPC in Germany. Data from quality reports and billing databases were analyzed to identify the number of RLT cycles and the increase in therapy providers. The study found a significant increase in the use of Lu-177-PSMA RLT, with more departments offering the treatment and a higher proportion of older patients receiving it.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Philipp E. Hartrampf, Franz-Xaver Weinzierl, Sebastian E. Serfling, Martin G. Pomper, Steven P. Rowe, Takahiro Higuchi, Anna Katharina Seitz, Hubert Kuebler, Andreas K. Buck, Rudolf A. Werner
Summary: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) has shown remarkable efficacy in patients with advanced prostate cancer. This study evaluated the side effect profile of the PSMA ligand [Lu-177]Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer. The results showed that no severe toxicities occurred with the use of this therapeutic agent.
Article
Radiology, Nuclear Medicine & Medical Imaging
Alexander Wurzer, Jan-Philip Kunert, Sebastian Fischer, Veronika Felber, Roswitha Beck, Francesco de Rose, Calogero D'Alessandria, Wolfgang Weber, Hans-Jurgen Wester
Summary: This study compared different radioligands to identify the most suitable one for 177Lu-radioligand therapy. The results showed that [177Lu]Lu-rhPSMA-10.1 exhibited the best pharmacokinetics in a mouse model, with the lowest kidney uptake and fastest excretion.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Medicine, Research & Experimental
Robert Seifert, Katharina Kessel, Katrin Schlack, Matthias Weckesser, David Kersting, Konstantin E. Seitzer, Manuel Weber, Martin Boegemann, Kambiz Rahbar
Summary: Lu-177-PSMA-617 (Lu-PSMA) therapy shows promise for end-stage prostate cancer patients, but early reduction in tumor volume may not necessarily predict overall survival. In patients with low PSMA expression, reduction in PSMA-TV might have a positive impact on OS.
Article
Oncology
Byoung Se Lee, Min Hwan Kim, So Young Chu, Woon Jung Jung, Hyeon Jin Jeong, Kyongkyu Lee, Hyeon Seok Kim, Mi Hyun Kim, Hee Seup Kil, Sang Jin Han, Yong Jin Lee, Kyo Chul Lee, Sang Moo Lim, Dae Yoon Chi
Summary: A novel therapeutic radioligand [Lu-177]1h was developed and evaluated in a mouse model with prostate-specific membrane antigen (PSMA)-expressing tumors, showing high tumor targeting and therapeutic efficiency. The compound [Lu-177]1h has the potential for further investigation in clinical trials for treating metastatic castration-resistant prostate cancer (mCRPC) based on the experimental results.
MOLECULAR CANCER THERAPEUTICS
(2021)
Review
Oncology
Konstantin Egon Seitzer, Robert Seifert, Katharina Kessel, Wolfgang Roll, Katrin Schlack, Martin Boegemann, Kambiz Rahbar
Summary: There are various treatment options available for patients with advanced prostate cancer, and Lu-PSMA radioligand therapy is one effective and relatively low side effect option. Researchers are focusing on minimizing adverse events and finding better treatment regimens. The efficacy of Lu-177-PSMA therapy has been confirmed, and future studies will focus on early disease stages and combination therapy.
Article
Radiology, Nuclear Medicine & Medical Imaging
Hojjat Ahmadzadehfar, Kambiz Rahbar, Richard P. Baum, Robert Seifert, Katharina Kessel, Martin Boegemann, Harshad R. Kulkarni, Jingjing Zhang, Carolin Gerke, Rolf Fimmers, Clemens Kratochwil, Hendrik Rathke, Harun Ilhan, Johanna Maffey-Steffan, Mike Sathekge, Levent Kabasakal, Francisco Osvaldo Garcia-Perez, Kalevi Kairemo, Masha Maharaj, Diana Paez, Irene Virgolini
Summary: In this multicenter analysis, mCRPC patients receiving Lu-177-PSMA-617 therapy had a significantly longer OS if they had not received prior chemotherapy.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Cardiac & Cardiovascular Systems
Susan Notohamiprodjo, Stephan G. Nekolla, Stephanie Robu, Alberto Villagran Asiares, Christian Kupatt, Tareq Ibrahim, Karl-Ludwig Laugwitz, Marcus R. Makowski, Markus Schwaiger, Wolfgang A. Weber, Zohreh Varasteh
Summary: This study demonstrated the feasibility of noninvasive imaging of fibroblast activation protein (FAP) expression after myocardial infarction (MI) using Ga-68-FAPI-04-PET, and showed that Ga-68-FAPI-04 uptake extends beyond the actual infarcted area in the infarct territory. Follow-up CMR confirmed the overestimation of the infarct size by Ga-68-FAPI-04 uptake.
JOURNAL OF NUCLEAR CARDIOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Nicolo Capobianco, Ludovic Sibille, Maythinee Chantadisai, Andrei Gafita, Thomas Langbein, Guenther Platsch, Esteban Lucas Solari, Vijay Shah, Bruce Spottiswoode, Matthias Eiber, Wolfgang A. Weber, Nassir Navab, Stephan G. Nekolla
Summary: This study developed a deep learning method that improved the accuracy and efficiency of prostate cancer staging by using training data from different radiotracers.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Thomas Langbein, Alexander Wurzer, Andrei Gafita, Andrew Robertson, Hui Wang, Ayca Arcay, Michael Herz, Hans-Juergen Wester, Wolfgang A. Weber, Matthias Eiber
Summary: This study found that the time between synthesis and injection and the decrease in specific activity of F-18-rhPSMA-7.3 had only minor effects on its biodistribution in patients. This suggests that F-18-labeled PSMA ligands can be produced centrally and shipped to PET clinics similar to F-18-FDG.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ping Wu, Yu Zhao, Jianjun Wu, Matthias Brendel, Jiaying Lu, Jingjie Ge, Alexander Bernhardt, Ling Li, Ian Alberts, Sabrina Katzdobler, Igor Yakushev, Jimin Hong, Qian Xu, Yimin Sun, Fengtao Liu, Johannes Levin, Guenter U. Hoeglinger, Claudio Bassetti, Yihui Guan, Wolfgang H. Oertel, Wolfgang Weber, Axel Rominger, Jian Wang, Chuantao Zuo, Kuangyu Shi
Summary: This study developed metabolic imaging indices based on deep learning to support the differential diagnosis of early idiopathic Parkinson disease (IPD) and atypical parkinsonian syndromes. The proposed indices showed high sensitivity and specificity in the blind-test cohort and were robust when dealing with discrepancies between populations and imaging acquisitions.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Andrei Gafita, Isabel Rauscher, Manuel Weber, Boris Hadaschik, Hui Wang, Wesley R. Armstrong, Robert Tauber, Tristan R. Grogan, Johannes Czernin, Matthew B. Rettig, Ken Herrmann, Jeremie Calais, Wolfgang A. Weber, Matthias R. Benz, Wolfgang P. Fendler, Matthias Eiber
Summary: The objective of this study was to develop a novel framework for response evaluation in prostate-specific membrane antigen PET/CT and determine its prognostic value for overall survival. The results showed that RECIP 1.0 had predictive value for OS and PSA 1 RECIP had higher predictive accuracy compared to PSA responses.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Susan Notohamiprodjo, Matthias Eiber, Christian Lohrmann, Wolfgang A. Weber
Summary: Vaccine-associated lymphadenopathy (VAL) is commonly observed in F-18-rhPSMA-7.3 PET examinations after COVID-19 vaccination. The uptake of PSMA ligand F-18-rhPSMA-7.3 by axillary lymph nodes increases after vaccination and can persist for up to 8 weeks. Moreover, metastatic axillary lymph nodes show a high SUVratio.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Nabeel Mansour, Stephan G. Nekolla, Eliana Reyes, George Angelidis, Panagiotis Georgoulias, Constantinos Anagnostopoulos, Paco Bravo, Isabella Bruno, Albert Flotats, Francisco Fuentes-Ocampo, Roberto Sciagra, Felix Keng, Lukas Kessler, Maria Papathanasiou, Prem Soman, Christoph Rischpler
Summary: CZT-MPI has higher diagnostic sensitivity in detecting coronary artery disease compared to conventional Anger-MPI, but it has reduced specificity and diagnostic accuracy. Experienced readers show higher inter-rater agreement and special training is required for non-experienced readers.
JOURNAL OF NUCLEAR CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Alberto Villagran Asiares, Teresa Vitadello, Borjana Bogdanovic, Esteban Lucas Solari, Lachlan McIntosh, Sylvia Schachoff, Tareq Ibrahim, Stephan G. Nekolla
Summary: This study investigated the impact of different cardiac gating methods on the assessment of cardiac function using FDG-PET. The results showed that the PET and MR-based cardiac function parameters were highly correlated, but the selected PET ECG gating method introduced variabilities and led to substantial disagreement in the assessment.
JOURNAL OF NUCLEAR CARDIOLOGY
(2023)
Article
Oncology
Carolin Kitzberger, Rebekka Spellerberg, Yang Han, Kathrin A. Schmohl, Christina Stauss, Christian Zach, Roland E. Kaelin, Gabriele Multhoff, Matthias Eiber, Franz Schilling, Rainer Glass, Wolfgang A. Weber, Ernst Wagner, Peter J. Nelson, Christine Spitzweg
Summary: In this study, genetically engineered MSCs carrying the NIS gene were injected into mice to treat experimental glioblastoma. The results showed that NIS-MSCs successfully homed to the tumor and expressed the NIS gene, and subsequent treatment with therapeutically effective radioiodide (131I) significantly delayed tumor growth and prolonged mouse survival.
CLINICAL CANCER RESEARCH
(2023)
Review
Urology & Nephrology
Robert Seifert, Louise Emmett, Steven P. Rowe, Ken Herrmann, Boris Hadaschik, Jeremie Calais, Frederik L. Giesel, Robert Reiter, Tobias Maurer, Matthias Heck, Andrei Gafita, Michael J. Morris, Stefano Fanti, Wolfgang A. Weber, Thomas A. Hope, Michael S. Hofman, Wolfgang Peter Fendler, Matthias Eiber
Summary: This study proposes the PROMISE V2 framework for standardized interpretation and reporting of PSMA-PET findings, aiming to improve communication between imaging experts and uro-oncologists. The framework integrates an updated miTNM system, improved assessment of local disease, and a slightly modified PSMA-expression score for clinical routine and research.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Wolfgang A. Weber, Henryk Barthel, Frank Bengel, Matthias Eiber, Ken Herrmann, Michael Schaefers
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Medicine, Research & Experimental
Volker Morath, Corinna Brandt, Friedrich-Christian Deuschle, Claudia T. Mendler, Birgit Blechert, Dominik Summer, Cyril Barinka, Clemens Decristoforo, Wolfgang A. Weber, Markus Schwaiger, Arne Skerra
Summary: Anticalin proteins targeting PSMA with tailored plasma half-life using PASylation technology are promising radioligands for PET imaging of xenograft tumors in mice. PET imaging using the FsC radiochelator is superior to Dfo radiochelator and adjusting the plasma half-life of Anticalin radioligands using PASylation technology can increase radioisotope accumulation within the tumor.
MOLECULAR PHARMACEUTICS
(2023)
Review
Radiology, Nuclear Medicine & Medical Imaging
Stephan G. Nekolla, Christoph Rischpler, Takahiro Higuchi
Summary: Noninvasive imaging techniques, such as SPECT, PET, CT, echocardiography, or MRI, have become essential in cardiovascular research and offer numerous advantages, such as high sensitivity and reliable quantification. Incorporating SPECT and PET imaging into a well-defined workflow similar to clinical imaging can effectively implement the concept of bench to bedside in cardiology translational research.
SEMINARS IN NUCLEAR MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Borjana Bogdanovic, Esteban L. Solari, Alberto Villagran Asiares, Sandra van Marwick, Sylvia Schachoff, Matthias Eiber, Wolfgang A. Weber, Stephan G. Nekolla
Summary: This study aimed to determine the effects of different PSMA PET timing on signal kinetics and its correlation with patients' PSA and Gleason scores. The results showed that the detection of tumors remained unchanged in static and dynamic scans. The activity concentration trend of lesions in pelvic lymph nodes and bones was mostly negative, while lesions in the prostate and prostatic fossa showed a positive trend. The correlation between dynamic parameters and PSA varied depending on the radiotracer used.
EUROPEAN JOURNAL OF HYBRID IMAGING
(2023)
Article
Oncology
Carolin Kitzberger, Khuram Shehzad, Volker Morath, Rebekka Spellerberg, Julius Ranke, Katja Steiger, Roland E. Kaelin, Gabriele Multhoff, Matthias Eiber, Franz Schilling, Rainer Glass, Wolfgang A. Weber, Ernst Wagner, Peter J. Nelson, Christine Spitzweg
Summary: New treatment strategies are urgently needed for glioblastoma (GBM) due to its resistance to standard treatment and poor prognosis. In this study, mesenchymal stem cells (MSCs) were engineered to express the sodium/iodide symporter (NIS) in response to interleukin-6 (IL-6) activation, and were successfully used to deliver NIS deep into the GBM tumor microenvironment. This novel tumor-targeted gene therapy approach resulted in enhanced radiotracer uptake, delayed tumor growth, and improved survival in mice with GBM.
MOLECULAR THERAPY-ONCOLYTICS
(2023)